Redeyes was again surprised by the magnitude of the volume decline in the third quarter.
Redeye reviews the case of Alzecure in the wake of the company’s pipeline progress and Q3 report.
Redeye provides a brief comment on the planned start of the phase II trial of Lipisense.
Investors House reported Q3 revenues of EUR 1.6m, 8% below our estimate.
The Q3 2023 results landed on the softer side and, in our view, Q4 may not bring clear relief just y...
Redeye saw a Q3 report that was both better and weaker than expected.
Redeye is making some small positive revisions to our forecasts and valuation following the Q3 repor...
Redeye retains its positive stance on Speqta following the Q3 report, as BrightBid continued its sol...
Weak North America behind Q3 miss, Q4 EBITA guided +25% y-o-y With 5% less employees vs year-end, vi...
Aktieanalytiker Mathias Carlson intervjuar VD Andreas Säfstrand efter publicerad Q3-rapport.
Redeye states that following a long streak of dissatisfactory sales, Neonode is now clearly re-direc...
Movinn A/S (“Movinn” or the “Company”) continued to demonstrate growth during the third quarter of 2...
Revenues and EBIT of Danish operations growth by 23% and 89% Delays meant that order intake dropped ...
Bolaget visar god motståndskraft och efterfrågan är bättre än förväntat.
Redeye has opened an Analyst Q&A in conjunction with the latest research update on Smart Eye.
Redeye strengthens its positive view of Vertiseit following a strong Q3 report, with significant imp...
Fortsatt pressat NAV NAV i kvartalet uppgick till 318 kr, vilket motsvarar en nedgång om 55% y/y och...
Stark lönsamhet och tillväxt Omsättningen i kvartalet uppgick till 29,9 mkr, vilket motsvarar en til...
Redeye comments on yesterday’s news regarding RLS’ terminated collaboration agreement with Convatec.
Redeye endorses today’s news that Egetis has outlicensed the rights to Emcitate in Japan to Fujimoto...
